Halozyme Therapeutics, Inc. Stock Performance
as on October 18, 2025 at 1:29 am IST
Day's Low
Day's High
$66.18$67.54
1.28%
Downside
0.75%
Upside
52 Week's Low
52 Week's High
$42.01$79.537.34%
Downside
18.59%
Upside
Halozyme Therapeutics, Inc. share price movements today
- Previous Close
- $66.88
- Open
- $67.41
- Volume
- 1.1M
- Day's Low - High
- $66.18 - $67.54
- 52 Week Low - High
- $42.01 - $79.5
Halozyme Therapeutics, Inc. Historical Returns
- 1 Month Return
- -12.58 %
- 3 Month Return
- + 18.74 %
- 1 Year Return
- + 27.41 %
- 3 Year Return
- + 45.69 %
- 5 Year Return
- + 133.11 %
Halozyme Therapeutics, Inc. Stock Fundamentals & Key Indicators
Check Halozyme Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$7.8B
EPS (TTM)
6.0485
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.85%
PE Ratio (TTM)
15.3
Industry PE ratio
8.355964912280701
PEG Ratio
-2.5
EBITDA
758.6M
Revenue (TTM)
1.2B
Profit Margin
47.28%
Return On Equity TTM
179.14%
Halozyme Therapeutics, Inc. Stock Valuation
Track how Halozyme Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Halozyme Therapeutics, Inc. in the last 5 years
Lowest (11.45x)
June 30, 2025
Industry (8.36x)
October 18, 2025
Today (15.30x)
October 18, 2025
Highest (39.94x)
December 31, 2020
Today’s Price to Earnings Ratio: 15.30x
Halozyme Therapeutics, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Halozyme Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $7.8B | 133.11% | 15.3 | 47.28% | |
| BUY | $63.1B | 231.27% | -505.15 | -12.96% | |
| NA | $36.7B | NA | NA | -3.89% | |
| BUY | $104.8B | 91.13% | 29.04 | 31.86% | |
| BUY | $60.3B | -3.62% | 14.35 | 31.37% |
Stock Returns calculator for Halozyme Therapeutics, Inc. Stock including INR - Dollar returns
The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Halozyme Therapeutics, Inc. investment value today
Current value as on today
₹1,32,223
Returns
₹32,223
(+32.22%)
Returns from Halozyme Therapeutics, Inc. Stock
₹27,428 (+27.43%)
Dollar Returns*
₹4,794 (+4.79%)
Analyst Recommendation on Halozyme Therapeutics, Inc. Stock
Based on 17 analysts
82.35%
Buy
17.65%
Hold
0.00%
Sell
Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Halozyme Therapeutics, Inc.. Average target price of $75.56
Halozyme Therapeutics, Inc. Share Price Target
Get share price movements and forecasts by analysts on Halozyme Therapeutics, Inc..
What analysts predicted
11.28%UPSIDE
Target Price
$75.56
Current Price
$67.04
Analyzed by
17 Analysts
Target
$75.56
Halozyme Therapeutics, Inc. target price $75.56, a slight upside of 11.28% compared to current price of $67.04. According to 17 analysts rating.
Halozyme Therapeutics, Inc. Stock’s Investor Sentiment and Interest
Search interest for Halozyme Therapeutics, Inc. Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:5% versus previous 30 day period
Halozyme Therapeutics, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Halozyme Therapeutics, Inc. Annual Profit & Loss
All numbers in Millions USD
Halozyme Therapeutics, Inc. Quarterly Cash Flow
All numbers in Millions USD
Halozyme Therapeutics, Inc. Annual Cash Flow
All numbers in Millions USD
Halozyme Therapeutics, Inc. News & Key Events
Today's Timeline - 23 September
Tue, 02:50 PM
-Halozyme reports strong Q1 2025 revenue growth and raised financial guidance, highlighting robust performance and new catalysts.
Tue, 06:53 PM
-Halozyme's collaboration deals and strong demand for subcutaneous formulations boost royalties and top line, with a Zacks Rank #1.
Tue, 08:40 PM
-Halozyme's European approval for Opdivo's subcutaneous formulation confirms growth potential, with significant revenue and profit increases.
Insights on Halozyme Therapeutics, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 118.09M → 165.16M (in $), with an average increase of 28.5% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, HALO stock has moved up by 4.6%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 264.86M → 325.71M (in $), with an average increase of 18.7% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.8% return, outperforming this stock by 35.4%
- NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 148.2% return, outperforming this stock by 102.5%
About Halozyme Therapeutics, Inc.
| Organisation | Halozyme Therapeutics, Inc. |
| Headquarters | 12390 El Camino Real, San Diego, CA, United States, 92130 |
| Industry | Health Technology |
| CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
| E-voting on shares | Click here to vote |
Key Management of Halozyme Therapeutics, Inc.
Name | Title |
|---|---|
Mr. Mark Snyder Esq. | Senior VP, General Counsel, Chief Compliance Officer & nd Secretary |
Ms. Cortney Caudill M.B.A. | Senior VP & COO |
Ms. Tram Bui | Head of Investor Relations & Corporate Communications |
Ms. Amy Marinne Fox | Chief Human Resources Officer |
Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer |
Mr. Paul Spence | Chief Commercial Officer |
Mr. Rhys de Callier | Chief Strategy Officer |
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director |
FAQs
What is Halozyme Therapeutics, Inc. share price today?
Halozyme Therapeutics, Inc. share price today is $67.04 as on at the close of the market. Halozyme Therapeutics, Inc. share today touched a day high of $67.54 and a low of $66.18.
What is the 52 week high and 52 week low for Halozyme Therapeutics, Inc. share?
Halozyme Therapeutics, Inc. share touched a 52 week high of $79.5 on and a 52 week low of $42.01 on . Halozyme Therapeutics, Inc. stock price today i.e. is closed at $67.04,which is 15.67% down from its 52 week high and 59.58% up from its 52 week low.
What is Halozyme Therapeutics, Inc.'s market capitalisation today?
Halozyme Therapeutics, Inc. market capitalisation is $0.01T as on .
How to invest in Halozyme Therapeutics, Inc. Stock (HALO) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Halozyme Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Therapeutics, Inc. Shares that will get you 0.0224 shares as per Halozyme Therapeutics, Inc. share price of $67.04 per share as on October 18, 2025 at 1:29 am IST.
What is the minimum amount required to buy Halozyme Therapeutics, Inc. Stock (HALO) from India?
Indian investors can start investing in Halozyme Therapeutics, Inc. (HALO) shares with as little as ₹87.954 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹879.54 in Halozyme Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Halozyme Therapeutics, Inc. share’s latest price of $67.04 as on October 18, 2025 at 1:29 am IST, you will get 0.1492 shares of Halozyme Therapeutics, Inc.. Learn more about
fractional shares .
What are the returns that Halozyme Therapeutics, Inc. has given to Indian investors in the last 5 years?
Halozyme Therapeutics, Inc. stock has given 133.11% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?